Calcitonin

Calcitonin100 IU/ml

Injection

Salmon Calcitonin

City Overseas Ltd.

Product Code : 2694
MRP 145.00
5% Off
Best PriceTk
/
1
Section

Medicine overview

Indications of Calcitonin 100 IU/ml

Calcitonin 100 IU/ml is indicated in Active Paget's disease in patients who do not respond to alternative treatments or for whom such treatments are not suitable; Hypercalcaemia.

Composition

Each ml Calcitonin 100 IU/ml injection contains- 50 or 100 I.U. salcatonin (present as Polyacetate polyhydrate) Sodium acetate 0.2% Glacial acetic acid 0.2% Sodium chloride 0.75% Calcitonin 100 IU/ml contains 32 amino-acids in linear sequence with a disulphide bridge at position 1 and 7 and a molecular weight of 3431.9 (free peptide). Salcatonin is a white or grey-tinged white amorphous powder. It is very soluble in water and very slightly soluble in alcohol.

Theropeutic Class

Hormone in bone formation by Inhibiting bone resorption

Pharmacology

Calcitonin is a polypeptide hormone produced by the ultimobranchial gland in non-mammalian vertebrates or by the mammalian thyroid parafollicular cells. It inhibits osteoclastic bone resorption and reduces bone turnover. It decreases tubular reabsorption and promotes renal excretion of Ca, Cl, Na, Mg, K and phosphate.

Dosage & Administration of Calcitonin 100 IU/ml

Intravenous (Adult)- Emergency treatment of hypercalcaemia: Up to 10 u/kg in 500 mL of sodium chloride 0.9% by slow IV infusion over at least 6 hr. Parenteral (Adult)- Adjunct in hypercalcaemia: SC/IM: 4 u/kg 12 hrly, may increase after 1-2 days to 8 u/kg 12 hrly to max 8 u/kg 6 hrly after 2 days. Alternatively, 100 u every 6-8 hr, increased after 1-2 days to max 400 u every 6-8 hr. Paget's disease of bone: SC/IM: 50 u 3 times wkly to 100 u/day. Nasal (Adult)- Nasal postmenopausal osteoporosis: 200 u/day, alternation nostrils everyday.

Dosage of Calcitonin 100 IU/ml

Intravenous (Adult)- Emergency treatment of hypercalcaemia: Up to 10 u/kg in 500 mL of sodium chloride 0.9% by slow IV infusion over at least 6 hr. Parenteral (Adult)- Adjunct in hypercalcaemia: SC/IM: 4 u/kg 12 hrly, may increase after 1-2 days to 8 u/kg 12 hrly to max 8 u/kg 6 hrly after 2 days. Alternatively, 100 u every 6-8 hr, increased after 1-2 days to max 400 u every 6-8 hr. Paget's disease of bone: SC/IM: 50 u 3 times wkly to 100 u/day. Nasal (Adult)- Nasal postmenopausal osteoporosis: 200 u/day, alternation nostrils everyday.

Interaction of Calcitonin 100 IU/ml

Concurrent use wth cardiac glycosides (e.g. digitalis) or Ca-channel blockers requires dosage adjustments of these drugs. May decrease serum concentration of lithium.

Contraindications

Hypersensitivity. Patients with hypocalcaemia.

Side Effects of Calcitonin 100 IU/ml

GI disturbances, dizziness, flushing, tingling of the hands, unpleasant taste, skin rash, abdominal pain, urinary frequency, tremor, inj site inflammation. Rarely, diabetogenic effect.

Pregnancy & Lactation

Pregnancy Category C. Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.

Precautions & Warnings

Skin test should be done before initiating therapy. Heart failure; renal impairment. Pregnancy, lactation, childn.

Overdose Effects of Calcitonin 100 IU/ml

Symptoms: Flushing, nausea, vomiting and dizziness. Management: Symptomatic and supportive treatment.

Storage Conditions

Store between 2-8° C.

Use In Special Populations

Renal Impairment: Dosage adjustment needed.

Drug Classes

Hormone in bone formation by Inhibiting bone resorption

Mode Of Action

Calcitonin is a polypeptide hormone produced by the ultimobranchial gland in non-mammalian vertebrates or by the mammalian thyroid parafollicular cells. It inhibits osteoclastic bone resorption and reduces bone turnover. It decreases tubular reabsorption and promotes renal excretion of Ca, Cl, Na, Mg, K and phosphate.

Pregnancy

Pregnancy Category C. Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.

Pediatric Uses

Renal Impairment: Dosage adjustment needed.
Disclaimer

The information provided is accurate to our best practices, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy. The absence of specific information about a drug should not be seen as an endorsement. We are not responsible for any consequences resulting from this information, so consult a healthcare professional for any concerns or questions.